PHASE-II STUDY OF 4'-(9-ACRIDINYLAMINO)METHANESULFON-M-ANISIDIDE (AMSA) IN METASTATIC BREAST-CANCER

Google Scholar
  • 1 January 1979
    • journal article
    • research article
    • Vol. 63  (11-1) , 1961-1964
Abstract
A phase II study of 4''-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) was carried out in previously treated patients with metastatic breast cancer. Four of 26 evaluable patients achieved a partial response and 4 showed a minor response. The maximum tolerated dose of AMSA was 30 mg/m2 per day .times. 3 days and the dose-limiting toxic effect was myelosuppression. Two AMSA responders had not responded to initial therapy with an adriamycin-containing regimen, indicating a lack of cross-resistance between these 2 DNA binders.